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a  b  s  t  r  a  c  t
In 2014, tofacitinib, a target-speciﬁc, synthetic disease modifying anti rheumatic drug
(DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil.
This  position paper aims to update the recommendations of the Brazilian Society of
Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, speciﬁcally
regarding the use of target-speciﬁc synthetic DMARDs. The method of this recommen-
dation consisted of a literature review of scientiﬁc papers held on the Medline database.
After  this review, a text was produced, answering questions in Pico structure, consider-
ing  efﬁcacy and safety issues of tofacitinib use for RA treatment in different scenarios
(such as ﬁrst-line treatment after failure with methotrexate [MTX] or other conventional
synthetic DMARDs after failure with biological therapy). Based on existing evidence, and
considering the available data on efﬁcacy, safety and cost of medications available to treat
the  disease in Brazil, the RA Commission of SBR, after a process of discussion and vot-
ing  on proposals, established the following position on the use of tofacitinib for treatment
of  RA in Brazil: “Tofacitinib, alone or in combination with MTX, is an alternative for RA
patients with moderate or high activity after failure of at least two  different synthetic
DMARDs and one biological DMARD.” The level of agreement with this recommendation
was 7.5.
This position may be reviewed in the coming years, in the face of a greater experience
with the use of this medication.
© 2015 Elsevier Editora Ltda. All rights reserved.
Posicionamento  sobre  o  uso  de  tofacitinibe  no  algoritmo  do  Consenso
2012  da  Sociedade  Brasileira  de  Reumatologia  para  o  tratamento  da
artrite  reumatoide
alavras-chave:
rtrite reumatoide
ratamento
rasil
ofacitinibe
r  e  s  u  m  o
Em 2014, o tofacitinibe, um medicamento modiﬁcador do curso da doenc¸a (MMCD) sin-
tético,  alvo-especíﬁco, inibidor seletivo das Janus quinases (JAK), foi aprovado para uso no
Brasil. Este documento de posicionamento tem o objetivo de atualizar as recomendac¸ões
da  Sociedade Brasileira de Reumatologia (SBR) sobre o tratamento da artrite reumatoide
(AR)  no Brasil, especiﬁcamente com relac¸ão ao uso de MMCD sintéticos alvo-especíﬁcos.
O  método dessa recomendac¸ão incluiu revisão bibliográﬁca de artigos cientíﬁcos, feita
na  base de dados Medline. Após a revisão, foi produzido um texto, que responde a
perguntas na estrutura Pico, e considera questões de eﬁcácia e seguranc¸a do uso do
tofacitinibe para tratamento de AR em diferentes situac¸ões (como primeira linha de trata-
mento, após falha ao metotrexato [MTX] ou outros MMCD sintéticos convencionais, após
falha da terapia biológica). Com base nas evidências existentes, e considerando os dados
disponíveis sobre eﬁcácia, seguranc¸a e custo das medicac¸ões disponíveis para tratamento
da  doenc¸a no Brasil, a Comissão de AR da SBR, após processo de discussão e votac¸ão
de  propostas, estabeleceu o seguinte posicionamento sobre o uso de tofacitinibe para o
tratamento da AR no Brasil: “Tofacitinibe, em monoterapia ou em associac¸ão ao MTX,
é  uma opc¸ão para os pacientes com AR em atividade moderada ou alta, após falha de
pelo  menos dois esquemas com diferentes MMCD sintéticos e um esquema de MMCD
biológico”. O grau de concordância com essa recomendac¸ão foi 7,5. Esse posicionamento
poderá ser revisto nos próximos anos, com a maior experiência adquirida com o uso do
medicamento.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
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Introduction
Rheumatoid arthritis (RA) is a systemic, autoimmune inﬂam-
matory disease characterized by involvement of the synovial
membrane of peripheral joints. It is estimated that the preva-
lence of RA is 0.5–1% of the population, mainly in women and
in people aged from 30 to 50 years.1
The treatment of RA has progressed substantially in recent
decades, due to a major breakthrough in understanding the
pathophysiological mechanisms of the disease, development
of new therapeutic classes and implementation of different
strategies of treatment and follow-up of patients, for instance,
intensive disease control and intervention in the early phase
of symptoms.1
In 2012 and 2013, the RA Commission of the Sociedade
Brasileira de Reumatologia (SBR) published a series of papers
aimed at producing recommendations on the diagnosis and
treatment of RA in Brazil. The purpose of these documents
was to establish consensus guidelines for the treatment of
RA in Brazil and to support Brazilian rheumatologists, using
evidence from scientiﬁc studies and the experience of a com-
mittee of experts on the subject in order to standardize the
therapeutic approach of RA in the Brazilian socioeconomic
context, maintaining the autonomy of the physician in the
indication/choice of treatment options available.2–5
At that time, the documents predicted that, due to the rapid
advances of knowledge in this ﬁeld of science, it would be nec-
essary to make periodic updates of such recommendations.
Since then, a drug belonging to a different class of pre-
viously existing drugs, tofacitinib, a synthetic, target-speciﬁc
disease-modifying anti-rheumatic drug (DMARD) and selec-
tive inhibitor of Janus kinase (JAK) has been approved for use in
Brazil.6 Tofacitinib was submitted for approval to the National
Health Surveillance Agency (ANVISA) on April 18, 2012 and
approved on December 8, 2014.7
Thus, a contingent update of the Treatment Guideline pre-
viously reported by SBR was in order to establish the position
of the RA Commission on the use of target-speciﬁc, synthetic
DMARDs in Brazil.
Objective
This position paper aims to update SBR recommendations on
the treatment of RA in Brazil, speciﬁcally regarding the use of
target-speciﬁc, synthetic DMARDs.
Methods
The literature review of scientiﬁc articles of this guideline
was conducted on MEDLINE database. The search for evidence
came from actual clinical settings, using the following key-
words (MeSH terms): Arthritis, Rheumatoid, Therapy, Efﬁcacy,
Safety, Prognosis, Remission,  Tofacitinib,  Herpes zoster vaccine.
Studies published up to May 2015 were evaluated.After a literature review, a text was produced, answering
questions in the PICO structure (Population/patient, Interven-
tion/indicator, Comparator/control, Outcome),8 taking into
account efﬁcacy and safety issues of tofacitinib use for 0 1 5;5 5(6):512–521
treatment of RA in different scenarios (such as ﬁrst-line
treatment after failure with methotrexate [MTX] or other
conventional synthetic DMARDs, after failure with biological
therapy).
Based on the review conducted and on expert opinion, pro-
posals of recommendations on the use of tofacitinib were
drawn up, subjected to successive rounds of voting among
members of the Committee gathered in person for this pur-
pose, pending approval of positioning (recommendations).
The degree of agreement with the text of the approved
recommendation on a numerical scale from 0 (strongly dis-
agree) to 10 (completely agree) was also established, with the
ﬁnal degree of agreement calculated by averaging the values
assigned individually by each of the members of the Commis-
sion. Depending on the approved recommendation, an update
of the ﬂowchart for the treatment of RA in Brazil was devel-
oped, considering a scenario of tofacitinib insertion.
Tofacitinib  –  general  aspects
Tofacitinib is a preferential inhibitor of JAK1/JAK3 (mem-
bers of the tyrosine kinase family, intracellular Janus kinase
that transduce cytokine-mediated signals through JAK-STAT
signaling pathway). This agent is indicated for patients with
active RA who have experienced treatment failure with syn-
thetic DMARDs, or with TNF inhibitors (TNFi). Tofacitinib
can be used in combination with synthetic DMARDs or as
monotherapy.6 The approved dosage for tofacitinib is 1 tablet
(5 mg)  twice daily.7
Regarding its main adverse effects, the safety proﬁle is
similar to biological immunomodulatory drugs with higher
incidence of serious infections, tuberculosis and herpes zoster
compared to the control group. The observed incidence of
herpes zoster has been higher than that reported for other
immunobiological agents, mostly milder cases. Laboratory
abnormalities observed include increases in total cholesterol,
fractions of low-density lipoprotein – LDL and high-density
lipoprotein – HDL, all reversible with speciﬁc treatment; neu-
tropenia and lymphopenia, increased liver enzymes, creatine
phosphokinase (CPK) and a slight increase in creatinine (not
associated with increased incidence of renal failure). The
increased incidence of malignancies, nonmelanoma skin can-
cers and lymphoproliferative diseases has not been observed
so far, but one must keep strict surveillance, considering that
this is a potent immunosuppressive agent. Brieﬂy, patients
with RA who will be treated with tofacitinib should be
assessed prior to treatment with respect to potential latent
TB (tuberculin skin test, chest X-ray and prior history of con-
tact with people infected with tuberculosis) and periodically
monitored with complete blood counts, assessment of renal
function, liver enzymes and lipidogram.9–15
Tofacitinib is an expensive drug, generally similar to bio-
logical DMARDs.
Is  tofacitinib  a  safe  and  effective  drug  for  the  treatment  of
RA patients,  as  ﬁrst  line  therapy?The use of tofacitinib as ﬁrst line therapy in patients with
RA has been evaluated in a study where patients who  had
received no MTX or who had not been treated with this drug
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n therapeutic doses, were randomized to take a dose of tofac-
tinib 5 mg  twice a day, tofacitinib 10 mg  twice a day, or MTX.14
ffectiveness
n this study, tofacitinib was superior to MTX  in controlling
igns and symptoms (ACR70 responses at 6 months: 25.5% in
he group receiving tofacitinib 5 mg  twice a day, 37.7% in the
roup of tofacitinib 10 mg  twice a day, and 12% of patients
eceiving MTX, p < 0.001. ACR70 = an improvement of 70% of
he American College of Rheumatology score – ACR). There
as also a signiﬁcantly greater reduction of structural dam-
ge in patients receiving tofacitinib compared to patients
eceiving MTX  (progression of Sharp index [modiﬁed] in six
onths = 0.2 points in the group treated with tofacitinib 5 mg
nd <0.1 points in the 10-mg group, compared to 0.8 in the
roup receiving MTX, p < 0.001 for both comparisons).14
afety
ive cases of neoplasm, including 3 cases of lymphoma, have
een reported in the group treated with tofacitinib, compared
o 1 case in the group receiving MTX. Infections, including
erpes zoster, were more  common in patients receiving tofac-
tinib, which also was associated with increases of creatinine,
DL and HDL.14
This study suggests that tofacitinib is effective in control-
ing signs and symptoms and in reducing structural damage as
 ﬁrst-line treatment in patients with RA. The use of tofacitinib
n combination with other DMARDs has not been evaluated in
his population. The beneﬁt of tofacitinib should be evaluated
n the context of the adverse effects described.
s  tofacitinib  a  safe  and  effective  drug  for  the  treatment  of
A patients  after  failure  with  MTX  or  other  synthetic
MARDs?
ffectiveness
ix systematic reviews with a meta-analysis evaluated the efﬁ-
acy of tofacitinib versus placebo in the treatment of patients
ith RA, following an inadequate response to a DMARD.16–21
hang et al.16 evaluated 10 randomized studies totaling 4,929
atients. Tofacitinib was superior to placebo in the evalu-
tion by ACR20 response (20% improvement in ACR score),
AQ-DI (Health Assessment Questionnaire – Disability Index)
core, and DAS28 (28-joint Disease Activity Score) in week 12
as monotherapy or in combination with MTX) and in week
4 (combined with MTX; monotherapy data not available).
ong et al.17 included ﬁve randomized trials totaling 1590
atients. Tofacitinib at doses of 5 mg  and 10 mg  (twice daily)
as superior to placebo on all evaluated efﬁcacy endpoints:
CR20 response, painful and swollen joint counts, visual
cales of pain and of the overall assessment by the physi-
ian and patient, HAQ-DI score and C-reactive protein (CRP)
evels.
Berhan18 conducted a meta-analysis of 8 randomized tri-
ls totaling 4,283 patients with RA, following an inadequate
esponse to a DMARD or a biological agent. The odds ratio
or ACR20 response was 4 times greater with tofacitinib
ersus placebo (OR = 4.15; 95% CI: 3.23–5.32). The results of
ofacitinib combined with MTX  or as monotherapy did not
iffer signiﬁcantly from each other. There was a decrease in 5;5 5(6):512–521 515
HAQ-DI score in patients treated with tofacitinib versus con-
trols (mean standardized difference = −0.62, 95% CI = −0.735
to −0.506). He et al.19 analyzed eight randomized studies,
totaling 3,791 patients with RA, following an inadequate
response to MTX. Higher ACR20 response rates at week
12 occurred with the use of tofacitinib 5 mg  (relative risk
[RR] = 2.20; 95% CI = 1.58–3.07) and 10 mg  (RR = 2.38; 95% CI:
1.81–3.14) versus placebo. The responses were maintained at
week 24.
Kawalec et al.20 compiled eight randomized studies com-
paring tofacitinib versus placebo in the treatment of RA, after
an inadequate response to a synthetic or biological DMARD.
Tofacitinib was superior to placebo in ACR20, ACR50 and
ACR70 response rates after 12 weeks of treatment (p < 0.0001
for all comparisons). Tofacitinib also resulted in an improve-
ment in HAQ-DI versus placebo. Kaur et al.21 conducted a
systematic review (without meta-analysis) of 8 phase II and
III randomized trials, comparing tofacitinib versus placebo in
patients with RA, following an inadequate response to a syn-
thetic or biological DMARD. Tofacitinib was superior to placebo
after 12 weeks of treatment in ACR20 and ACR50 responses
and in decreases in HAQ-DI score. Together, the six systematic
reviews included 12 publications, related to 11 randomized
clinical trials.9–13,22–28 The ﬁndings corroborate the effective-
ness of tofacitinib combined to MTX or as monotherapy in the
treatment of RA.
Two randomized studies evaluated tofacitinib and adal-
imumab in parallel groups versus placebo.10,27 No direct
comparison between tofacitinib and adalimumab was held. In
the ﬁrst study (n = 384), ACR20 response rates at week 12 were
59.2% and 70.5% for tofacitinib at doses of 5 mg  and 10 mg,
respectively, and 22% in the placebo group (p < 0.0001). Dif-
ferences favoring tofacitinib were also found in ACR50 (50%
improvement in ACR score) and ACR70 responses, and in
DAS28, HAQ-DI and SF-36 (Medical Outcomes Study 36-Item –
Short-Form Health Survey) scores, and also in the evaluation of
fatigue by FACIT-F (Functional Assessment of Chronic Illness
Therapy – Fatigue). In this study, adalimumab did not differ
signiﬁcantly from placebo with respect to most outcomes.27 In
another study (n = 717), ACR20 response rates after 6 months
of treatment were 51.5% and 52.6% in groups with tofacitinib
5 mg  and 10 mg  respectively; 47.2% in groups treated with
adalimumab; and 28.3% in the placebo group (p < 0.001 for all
comparisons vs. placebo). Also a higher number of subjects in
remission (DAS28 ≤ 2.6) were observed after 6 months in the
active treatment groups. The responses were maintained until
the 12th month of follow-up.10
van der Heijde et al.11 conducted a randomized, double-
blind, placebo-controlled trial to assess the prevention of
structural damage by tofacitinib in 797 RA patients. After 6
months of treatment (interim analysis of data), tofacitinib
10 mg  (twice daily) signiﬁcantly reduced the progression of the
total modiﬁed Sharp/van der Heijde score versus placebo.
The data available from phase II and III studies indicate
that tofacitinib is effective in the treatment of RA after failure
with a DMARD.Safety
The tofacitinib safety outcomes reported here are based
on long-term extension studies, which encompassed 4,102
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patients from phase I,29,30 II,22,23,25,27 and III9–13,28,31 random-
ized clinical trials. Overall, discontinuation of treatment was
observed in 842 patients (20.8%), and 437 patients (10.7%)
were discontinued due to adverse events. The main adverse
events associated with discontinuation were infections and
laboratory abnormalities (anemia, neutropenia, lymphopenia,
changes in liver enzymes, and serum cholesterol, LDL and
creatinine increases).32
The most common infections were nasopharyngitis, upper
respiratory tract infection and urinary tract infection. Infec-
tions of particular interest as herpes zoster and tuberculosis
were more  often observed in Asian patients, for whom the
risk of developing herpes zoster was higher (6.7 events per
100 patient-years) compared to Caucasian patients (3.7 events
per 100 patient-years).32 The risk of developing tubercu-
losis was evaluated in a model by Maiga et al.33 These
authors showed that tofacitinib can induce reactivation of
latent tuberculosis infection (LTBI), because the drug induces
increases in mycobacteria replication. Long-term extension
studies reported the occurrence of 10 cases of tuberculo-
sis in 4,102 patients, reinforcing the recommendation of a
LTBI survey before starting treatment with tofacitinib.32 The
most common gastrointestinal manifestations were diarrhea
(4.4%), nausea (3.3%) and gastritis (2.5%). Despite reports of
gastrointestinal perforation, the occurrence of these adverse
events did not differ from those occurring with biological and
non-biological DMARD users (0.05–0.17 events per 100 patient-
years).34,35
Regarding laboratory changes, these effects were char-
acterized as mild to moderate, not being, in most cases,
required a permanent discontinuation of treatment with
tofacitinib.32 As to anemia, a hemoglobin drop below 7 g/dL
or a decrease greater than 3 g/dL was observed in 1% of
patients, with the majority of patients presenting anemia
had decreases in hemoglobin values in the order of 1–2 g/dL
(12.7%). The incidence of neutropenia was 4.9%, and no
patients had neutrophil counts under 500 cells/mm3; 3.9% had
neutrophil counts of 1500–1999 cells/mm3. Liver enzyme ele-
vations occurred in 35% of patients, and the most common
ﬁnding was a onefold increase of normal value (29.7%). These
changes were transient and did not result in treatment discon-
tinuation. A threefold increase of the normal value occurred
in 1.2% of patients, whose values returned to normal after
discontinuation of tofacitinib. An increase of creatine was
observed in 3.3% of patients; this ﬁnding was reversible and
transient, and does not seem to be related to acute renal fail-
ure or progressive worsening of renal function.32,36 The use
of tofacitinib increases serum cholesterol, LDL and HDL, with
a mean elevation of cholesterol of 13 mg/dL, a value similar
to that observed with HDL elevation. It was not yet properly
established the real meaning of these moderate elevations in
lipid proﬁle.37
Regarding the occurrence of malignancies, Curtis et al. ana-
lyzed 5,671 tofacitinib users in 6 phase II studies, 6 phase III
studies and two long-term extension studies. They observed
the occurrence of 107 malignancies (excluding non-melanoma
skin cancer). The most common neoplasm was lung cancer
(n = 24), followed by breast cancer (n = 19), lymphoma (n = 10)
and gastric cancer (n = 5). The malignancy rate by six-month
intervals of exposure to tofacitinib remained stable during the 0 1 5;5 5(6):512–521
period of time analyzed. The incidence rates of these neo-
plasms were as expected for RA patients with moderate or
severe activity.38
Is  tofacitinib  a  safe  and  effective  drug  for  treatment  of  RA
patients  after  failure  with  biological  drugs?
Effectiveness
A phase III, double-blind, placebo-controlled, parallel group
trial with six months’ duration was conducted in patients with
moderate to severe RA who had not responded or were intol-
erant to one or more  TNFis.12 All patients involved in the study
were using, and remained in use, of MTX. 399 patients were
included (133 in tofacitinib 5 mg twice daily group, 134 in tofac-
itinib 10 mg  twice daily group, and 132 in the placebo group).
After three months, patients in the placebo group were dis-
tributed by tofacitinib 5 mg or 10 mg  groups. Most patients
were female (80.3%), white (84.8%) and with a mean age of
54.4–55.4 years and a mean disease duration of 11.3–13 years.
The mean number of prior treatments with TNFi was 1.4–1.5
(64% had been previously treated with a TNFi: 26% with two
and 8% with three or more  treatments). TNFi had been dis-
continued for lack of efﬁcacy in 65.2%, for lack of efﬁcacy
and intolerance in 19.8%, and for intolerance only in 13.8%.
Baseline mean values of HAQ-DI and DAS28-ESR (erythrocyte
sedimentation rate) ranged from 1.5–1.6 and 6.4–6.5, respec-
tively. The primary objectives of the study were to evaluate the
ACR20 response rate, mean HAQ-DI change from the onset of
treatment, and disease activity index (DAS28-VHS) rates <2.6
at the end of three months.12
After three months, the ACR20 response of tofacitinib 5-
mg  group was 41.7% (55 of 132; 95% CI: 6.06–28.41; p = 0.0024)
versus placebo 24.4% (32 of 131). Also after three months, the
ACR50 response to tofacitinib 5-mg group was 26.5% (35 of
132; [9.21–27.02]; p < 0.0001) versus placebo (8.4%; 11 of 131) and
the ACR70 response to tofacitinib 5-mg group was 13.6% (18 of
132; [5.89–18.32]; p < 0.0001) versus placebo, 1.5% (2 of 131). Still,
after three months, the mean variation of least mean least
squares (LMS) versus baseline for HAQ-DI was −0.43 ([95% CI:
−0.36 to −0.15]; p < 0.0001) for tofacitinib 5-mg group versus
placebo (−0.18). Improvement in HAQ-DI ≥0.22 was observed
in 54.2% (71 of 131; [1.76–25.71]; p = 0.0245) for tofacitinib 5-
mg  group versus placebo, 40.5% (53 of 131). Improvement in
HAQ-DI ≥0.5 was observed in 35.9% (47 of 131; [4.52–26.01];
p = 0.0053) for tofacitinib 5-mg group versus placebo, 20.6% (27
of 131). The proportion of patients with DAS28 <2.6 after three
months was 6.7% (8 of 119; [0–10.10]; p = 0.0496) for tofacitinib
5-mg group versus placebo (1.7%, 2 of 120). After six months,
this ﬁgure increased to 8.2% (10 of 122) with tofacitinib 5 mg
versus placebo, 5.0% (6 of 120). In the third and sixth months,
remission (deﬁned by Boolean criteria) was reached by 6.1% (8
of 132; [1.99–10.13]; p = 0.0035) for tofacitinib 5-mg group versus
0% in the placebo group.12
Regarding the outcomes reported by patients (PRO – Patient
Reported Outcomes) after three months, the proportions of
patients with greater than or equal answers to minimum
clinically important difference (MCDI) were: 1. Overall assess-
ment of disease activity – 41.88% in the placebo group versus
64.91% in tofacitinib 5-mg group (p < 0.001); 2. Pain – 39.13%
in the placebo group versus 69.30% in tofacitinib 5-mg group
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Monotherapy
(preferably MTX)
First
line
Failed after 3 months
Partial response to MTX Intolerance to MTX
In all stages:
Prednisone or equivalent
(use the shortest time/needed
dose possible)
Intra-articular corticosteroid
and/or NSAID and/or analgesics
Exchange between
synthetic DMARDs
Synthetic DMARD (preferably MTX)
+
Biological DMARD
(TNFi as first choice or ABAT or TOCI)
Active disease:
Consider DAS, aiming remission or at
least low disease activity
Failure or intolerance to biological DMARD:
Keep synthetic DMARD (preferably MTX)
and switch biological DMARD to other
TNFI or ABAT or RTX or TOCI or TOFA
Failed after 3 months
Failed after 3 months
Failed after 3 months
Failed after 3 months
Second
line
Third
line
ABAT, abatacept; NSAID, nonsteroidal anti-inflammatory agent; DMARD, disease modifying antirheumatic drug;
MTX, methotrexate; RTX, rituximab; TNFi, tumor necrosis factor inhibitors; TOFA, tofacitinib; TOCI, tocilizumab.
Combination of synthetic
DMARDs
Fig. 1 – Updated ﬂowchart of drug treatment for rheumatoid arthritis in Brazil, proposed by the Commission on Rheumatoid
Arthritis of the Brazilian Society of Rheumatology.
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(p < 0.0001); 3. Fatigue (FACIT) – 38.60% in the placebo group
versus 61.54% in tofacitinib 5-mg group (p < 0.0001); 4. SF-36v2
– physical component – 49.14% in the placebo group versus
67.80% in tofacitinib 5-mg group (p < 0.05), and 5. SF-36v2 –
mental component – 37.07% in the placebo group versus 54.24%
in tofacitinib 5-mg group (p < 0.05).39
In another phase III, double-blind, placebo-controlled trial,
611 patients with active RA refractory or intolerant to at least
one synthetic or biological DMARD were randomized in groups
of monotherapy with tofacitinib 5 mg  twice daily (n = 243),
tofacitinib 10 mg  twice daily (n = 245) and placebo (n = 122).13 A
sub-analysis with patients who  had already made use of TNFi
or other biological agent revealed that 18 of 46 (42.9%) patients
in the tofacitinib 5-mg group and 6 of 34 (17.7%) patients in
the placebo group achieved ACR 20 response criteria at three
months.
Safety
In the ﬁrst three months of the phase III trial, 145 adverse
events were reported in 71 of 133 patients in tofacitinib 5-
mg group (53.4%) versus 167 adverse events in 75 of 132
patients in the placebo group (56.8%). During this period,
the most common adverse events were diarrhea (13 of 267;
4.9%), nasopharyngitis (11 of 267; 4.1%), headache (11 of 267;
4.1%) and urinary tract infection (8 of 267; 3.0%) in tofaci-
tinib (5 mg  and 10 mg)  groups; and nausea (9 of 132; 6.8%) in
the placebo group. Serious adverse events occurred in 4 of
267 patients (1.5%) treated with tofacitinib (2 in 5-mg group
and 2 in 10-mg group), and 6 in 132 patients (4.5%) in the
placebo group. No serious infectious event was reported. Eight
patients (6.0%) discontinued the protocol because of adverse
events in tofacitinib 5-mg group versus 7 (5.3%) in the placebo
group.12,13
Is  there  evidence  for  indication  of  the  use  of  herpes  zoster
vaccine  in  tofacitinib  users?
The prevention of herpes zoster (HZ) is of great interest to RA
patients, since they are in greater risk of infection compared
to the general population.40,41
In Brazil, the vaccine for HZ prevention (and its compli-
cations) contains live attenuated virus, with 14 times more
antigens than the varicella vaccine can have from the same
manufacturer. HZ vaccine is licensed for use in people over
50 years old. According to the Immunization Guide prepared
in 2014 by the Brazilian Society of Immunizations (BSIm) and
the Brazilian Society of Rheumatology (SBR), its use should
be avoided in patients with severe drug immunosuppression
or with immunosuppression caused by disease; however, this
vaccine may be indicated in patients with mild immunosup-
pression. Patients with chronic diseases can be vaccinated,
except in case of severe immunosuppression and if in treat-
ment with biological agents.42
At the moment, however, there is limited information on
the safety and efﬁcacy of this vaccine in RA patients. There
are few studies evaluating its value in patients being sub-
mitted to different immunosuppressive regimens, including
tofacitinib.40
Taking into account that vaccination is a preventive mea-
sure with the greatest impact on reducing the incidence of 0 1 5;5 5(6):512–521
infection in any age group, the SBR Consensus of 2012 on vac-
cination in RA patients recommends a review and updating of
the immunization card before the use of synthetic or biolog-
ical DMARDs, including the vaccine against herpes zoster in
patients over 50 years old.43
Likewise, ACR recommends vaccination prior to the
onset of treatment with synthetic or biological DMARDs
in RA patients over 50 years old. During the use of syn-
thetic DMARDs, the vaccine may also be applied, but
this is not recommended during the use of biological
DMARDs.1,3,4 The use of tofacitinib was not addressed in these
recommendations.40,44,45
Importantly, the vaccine is not available on the public
Health Service and is not covered by most health plans and
health insurance companies.
RA  Commission  of  SBR  position  on  the  use  of  tofacitinib
for the  treatment  of  RA  in  Brazil
Based on previous evidence and considering the available data
on efﬁcacy, safety and cost of medications available to treat the
disease in Brazil, the RA Commission of SBR, after a process of
discussion and voting on proposals, established the following
position on the use of tofacitinib for treatment of RA in Brazil:
“Tofacitinib, alone or in combination with MTX, is an alterna-
tive for RA patients with moderate or high activity after failure
of at least two different synthetic DMARDs and one biological
DMARD.” The level of agreement with this recommendation
was 7.5.
The RA Commission considers it necessary to establish a
timely and objective recommendation, which would help the
rheumatologist in his/her decision making about the use of
this new medication in RA treatment ﬂowchart. But we  also
considered – and this was quite clear on the basis of a fairly
debated voting and discussion process – that, under certain
conditions and in very speciﬁc clinical scenarios, the earlier
use of tofacitinib could be indicated, at the physician’s discre-
tion, since, as shown, there is evidence of efﬁcacy of this drug
at different times in the treatment of RA.
The decision of this Commission of experts, to indicate the
use of tofacitinib after failure of at least two different synthetic
DMARDs and one biological DMARD, took into account mainly
the still restricted period of post-marketing experience. We
believe that this aspect limits the information relevant on
safety, compared to other medications already in use for RA
treatment. This position may be reviewed in coming years, in
the face of the acquisition of a greater experience with the use
of this drug.
RA  treatment  ﬂow  chart  update  in  Brazil
Fig. 1 summarizes the updated ﬂowchart of drug treatment for
RA in Brazil, as proposed by the RA Committee of SBR.
ConclusionThe current position of the RA Commission of SBR is that,
despite the proven clinical efﬁcacy of tofacitinib in patients
with RA who have failed synthetic or biological DMARDs, it
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s suggested that its use is considered in a scenario of failure
n at least two synthetic DMARD and at least one biological
MARD, thanks to a lesser long-term clinical experience with
his drug in clinical practice.
This positioning may be revised over time, in the face of the
cquisition of a greater experience with the use of this drug.
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